| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
36,450,000 |
| Market
Cap: |
44.10(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.578 - $1.62 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AVROBIO is a clinical-stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Co.'s initial focus is on a group of rare genetic diseases referred to as lysosomal disorders, some of which are mainly managed with enzyme replacement therapies. Co.'s pipeline consists of five lentiviral-based gene therapy programs: AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Resnick Gene |
Chief Medical Officer |
• – – |
2009-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
4,285,714 |
15,302,381 |
|
- |
|
| Comvest Investment Partners Ii Llc |
10% Owner |
– – • |
2008-06-27 |
4 |
A |
$0.00 |
$0 |
I/I |
4,800,000 |
321,839,235 |
|
- |
|
| Resnick Gene |
CHIEF MEDICAL OFFICER |
• – – |
2007-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
600,000 |
11,016,667 |
|
- |
|
| Codeanne Christopher George |
Chief Financial Officer |
• – – |
2007-10-31 |
4 |
A |
$0.16 |
$50,000 |
D/D |
312,500 |
312,500 |
|
- |
|
| Lavin Philip T |
EXECUTIVE CHAIRMAN |
• • • |
2007-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
9,600,000 |
107,236,277 |
|
- |
|
| Deegan Glenn E |
VP, GENL COUNSEL & SECY |
• – – |
2007-10-31 |
4 |
A |
$0.16 |
$12,500 |
D/D |
78,125 |
78,125 |
|
- |
|
| Weissbach Markus |
CHIEF EXECUTIVE OFFICEROfficer |
• – – |
2007-10-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
312,500 |
|
- |
|
| Comvest Investment Partners Ii Llc |
10% Owner |
– – • |
2007-10-31 |
4 |
A |
$0.00 |
$0 |
I/I |
52,800,000 |
317,039,235 |
|
- |
|
| Comvest Investment Partners Ii Llc |
10% Owner |
– – • |
2006-11-28 |
5 |
A |
$0.00 |
$0 |
I/I |
71,428,500 |
264,239,235 |
|
- |
|
| Lavin Philip T |
EXECUTIVE CHAIRMAN |
• • • |
2006-11-28 |
4 |
A |
$0.00 |
$0 |
D/D |
61,036,369 |
97,636,277 |
|
- |
|
| Falk Michael |
Director |
– • • |
2006-08-29 |
4 |
A |
$0.00 |
$0 |
I/I |
49,229,300 |
49,229,300 |
|
- |
|
| Lavin Philip T |
Chief Executive Officer |
• – • |
2006-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
6,714 |
6,714 |
|
- |
|
| Lavin Philip T |
Chief Executive Officer |
• – • |
2006-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
36,599,908 |
36,599,908 |
|
- |
|
| Sollenne Peter R |
CEO |
• • – |
2005-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
987,000 |
987,000 |
|
- |
|
| Allocca Tony |
Secretary |
• – – |
2005-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
11,914,500 |
11,914,500 |
|
- |
|
| Alberts Kelly |
President |
• • – |
2005-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
15,298,500 |
15,298,500 |
|
- |
|
| Rohny Kamill |
Shareholder |
– – – |
2004-06-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(28,125,000) |
1,875,000 |
|
- |
|
| Sollenne Peter R |
CEOOfficer |
• • – |
2004-06-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
385,000 |
|
- |
|
| Allocca Tony |
VP Ops.Officer |
• • • |
2004-06-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,647,500 |
|
- |
|
| Alberts Kelly |
President/COOOfficer |
• • • |
2004-06-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,967,500 |
|
- |
|
| Rohny Kamill |
CEOOfficer |
• • • |
2004-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,000,000 |
|
- |
|
21 Records found
|
1
|
Page 1 of 1 |
|
|
0.02 (2.11%) 
